Bristol-Myers Squibb Slips to 88th in Trading Volume Despite Strong Q1 Performance

On April 25, 2025, Bristol-Myers Squibb (BMY) experienced a significant decline in trading volume, with a total turnover of $775 million, marking a 22.1% decrease from the previous day. This decline placed BMY at the 88th position in terms of trading volume for the day. The stock price of BMY also decreased by 1.62%.

Bristol-Myers Squibb demonstrated a strong financial performance in the first quarter of 2025, transitioning from a net loss to a profit. The company's revenue for the quarter reached $11.2 billion, driven by an 18% growth in its portfolio. This robust performance led to an upward revision of the company's full-year revenue guidance to a range of $45.8 billion to $46.8 billion, reflecting the strength of both new and existing product lines.

In addition to the revenue growth, Bristol-Myers Squibb reported a gross margin of 73% and a diluted earnings per share (EPS) of $1.80 for the first quarter. The company also raised its 2025 non-GAAP EPS guidance, indicating a positive outlook for the remainder of the year. The equal revenue contribution from BMY's growth and legacy portfolios, each generating $5.6 billion, was a significant development in the first quarter.